Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free LABT Stock Alerts

Lakewood-Amedex Biotherapeutics (LABT) Competitors

Lakewood-Amedex Biotherapeutics logo
$0.71 +0.00 (+0.28%)
As of 03:34 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

LABT vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Lakewood-Amedex Biotherapeutics stock or one of its competitors? MarketBeat compares Lakewood-Amedex Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lakewood-Amedex Biotherapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Lakewood-Amedex Biotherapeutics compare to Ainos?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Ainos (NASDAQ:AIMDW) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Ainos. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Ainos'average media sentiment score.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Neutral
Ainos Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

Summary

Lakewood-Amedex Biotherapeutics and Ainos tied by winning 1 of the 2 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Lakewood-Amedex Biotherapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$586.32MN/AN/AN/AN/A
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Alvotech. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Alvotech. Alvotech's average media sentiment score of 0.00 equaled Lakewood-Amedex Biotherapeutics'average media sentiment score.

Company Overall Sentiment
Alvotech Neutral
Lakewood-Amedex Biotherapeutics Neutral

Summary

Alvotech and Lakewood-Amedex Biotherapeutics tied by winning 1 of the 2 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Aravive?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Aravive (NASDAQ:ARAV) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Aravive. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Neutral
Aravive Neutral

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

Lakewood-Amedex Biotherapeutics has higher earnings, but lower revenue than Aravive.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A
Aravive$6.99M0.42-$66.21M-$0.90N/A

Summary

Aravive beats Lakewood-Amedex Biotherapeutics on 3 of the 4 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Atlantic Coastal Acquisition Corp. II?

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

In the previous week, Lakewood-Amedex Biotherapeutics had 1 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 1 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.

Company Overall Sentiment
Lakewood-Amedex Biotherapeutics Neutral
Atlantic Coastal Acquisition Corp. II Neutral

Company Net Margins Return on Equity Return on Assets
Lakewood-Amedex BiotherapeuticsN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

Summary

Lakewood-Amedex Biotherapeutics beats Atlantic Coastal Acquisition Corp. II on 1 of the 1 factors compared between the two stocks.

How does Lakewood-Amedex Biotherapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, profitability and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Lakewood-Amedex BiotherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Lakewood-Amedex Biotherapeutics N/A N/A N/A

In the previous week, Biofrontera and Biofrontera both had 1 articles in the media. Biofrontera's average media sentiment score of 0.00 equaled Lakewood-Amedex Biotherapeutics'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biofrontera
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lakewood-Amedex Biotherapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Biofrontera beats Lakewood-Amedex Biotherapeutics on 1 of the 1 factors compared between the two stocks.

Get Lakewood-Amedex Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LABT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LABT vs. The Competition

Export
MetricLakewood-Amedex BiotherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market CapN/A$946.94M$4.27B$12.47B
Dividend YieldN/A4.84%5.93%5.27%
P/E RatioN/A1.4621.9825.84
Price / SalesN/A132.88232.3168.19
Price / CashN/A20.0755.6856.67
Price / BookN/A7.7232.367.15
Net IncomeN/A-$3.91M$112.32M$336.98M
7 Day Performance-5.18%2.65%3.84%3.35%
1 Month Performance-80.49%75.20%4.84%3.46%
1 Year PerformanceN/A124.30%15.65%36.35%

Lakewood-Amedex Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LABT
Lakewood-Amedex Biotherapeutics
N/A$0.71
+0.3%		N/AN/A$0.00N/AN/A5
AIMDW
Ainos
N/A$0.06
-13.3%		N/A-37.6%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.19
-5.1%		N/A-90.0%$0.00$586.32MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
-2.9%		N/A-77.3%$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LABT) was last updated on 5/27/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
The AI stocks about to become worthless (and one that isn't)
Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...
InvestorPlace | Sponsoredtc pixel